<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The testing kit of second generation for serum anti-HCV was used in 82 cases of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) </plain></SENT>
<SENT sid="1" pm="."><plain>The results showed that positive rate was 69.4% (43/62) in the patients of AA with transfusion, this was significantly higher than that in the patients of AA without transfusion </plain></SENT>
<SENT sid="2" pm="."><plain>There was no difference of anti-HCV antibody positive rate between <z:hpo ids='HP_0011010'>chronic</z:hpo> AA and <z:hpo ids='HP_0011009'>acute</z:hpo> AA (P &gt; 0.05), incidence rate of post-transfusion <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C (PTHC) in AA was 33.9% (21/62), among which the incidence rate in <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> AA were 68.8% (11/16) and 21.7% (10/46) respectively (P &lt; 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>The anti-HCV positive patients were divided into two groups: PTHC and non-PTHC, there was no statistical difference of their transfusion volume, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, white blood cell between these groups </plain></SENT>
<SENT sid="4" pm="."><plain>Response rate of AA was lower in anti-HCV positive patients than that in negative patients (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo>, icteric PTHC was predominant in patients with AA </plain></SENT>
<SENT sid="6" pm="."><plain>The patients with AA complicated with PTHC was liable to bleed and be infected </plain></SENT>
<SENT sid="7" pm="."><plain>PTHC has been an important complication in patients with AA </plain></SENT>
<SENT sid="8" pm="."><plain>The better response was obtained by TCM-WM therapy in the patients </plain></SENT>
</text></document>